Retatrutide FDA approval status: where things stand

• FDA (United States) — Investigational. No NDA/BLA on file. Not in the Orange Book. [2]
• EMA (European Union) — No marketing authorization application on file.
• MHRA (United Kingdom) — Not authorized.
• PMDA (Japan), TGA (Australia), Health Canada — Not authorized.

Any product advertised as "retatrutide for sale" or labeled "research only" is not the same drug being evaluated in clinical trials and is not approved for human use.

1. 2022

   Phase 1 first-in-human studies

   Single- and multiple-ascending dose studies completed.

2. 2023

   Phase 2 readouts published

   Obesity (NEJM) and type 2 diabetes (Lancet) trials published.

3. 2023–2024

   TRIUMPH Phase 3 program launched

   Pivotal trials initiated across four indications.

4. 2026

   Initial TRIUMPH topline readouts (expected)

   Lilly guidance points to first Phase 3 readouts during 2026.

5. 2026–2027

   FDA submission window (projected)

   Following positive readouts, NDA submission typically follows in months.

6. 2027

   Possible US approval decision (projected)

   Standard FDA review of a complete submission takes 10–12 months.

Real-world FDA review timelines are highly variable. Drugs with priority review or breakthrough designation move faster. Standard review of a complete submission for a new molecular entity typically takes 10 to 12 months from filing acceptance.

For obesity, the FDA generally looks for both meaningful average weight loss (often a benchmark of ≥5% placebo-adjusted) and a clear proportion of responders achieving categorical thresholds. Retatrutide's Phase 2 numbers comfortably exceed those bars — the question is whether Phase 3 confirms them in larger, longer trials.

Safety review will focus on the cardiovascular profile (given the Phase 2 heart-rate signal), pancreatic and gallbladder event rates, and longer-term tolerability beyond the 48-week window of Phase 2.

Lilly has historically pursued near-simultaneous US and EU filings for major obesity and diabetes products. Once a US submission is accepted, an EMA application typically follows within months, with a Centralised Procedure decision running on a parallel timeline.

Specific national approvals — UK (MHRA), Australia (TGA), Canada (Health Canada), Japan (PMDA) — generally follow major regulators with additional months of review.

When tirzepatide was approved for obesity in late 2023, it took months for commercial launch and significantly longer for insurance coverage to develop in the United States. Expect a similar pattern for retatrutide:

• First 3–6 months — commercial launch, cash-pay channels, telehealth platforms add the drug to formulary.
• 6–18 months — broader retail-pharmacy availability, initial PBM coverage decisions.
• 18+ months — wider commercial-payer coverage, possible direct-to-consumer self-pay tiers, supply normalization.

Medicare coverage of obesity-only indications remains constrained by current statute as of 2026; this may evolve.

The TRIUMPH program and adjacent retatrutide studies are listed on ClinicalTrials.gov. Most pivotal arms are now closed to new enrollment, but extension studies and adjacent indications continue to enroll on a rolling basis. [1]

Lilly has not announced an expanded-access program for retatrutide. Expanded access is typically reserved for serious conditions without satisfactory alternatives, and FDA-approved GLP-1 alternatives currently exist for both obesity and type 2 diabetes.